粪便钙卫蛋白升高与儿童及青少年炎症性肠病临床缓解期后续症状性复发相关
本研究为横断面队列研究,纳入114例临床缓解≥3个月的儿童炎症性肠病患者,评估基线粪便钙卫蛋白(FC)和C反应蛋白(CRP)对后续12个月内症状性复发的预测价值。结果显示基线FC和CRP均能预测6个月内症状性复发,FC预测准确性良好(AUC 0.82),最佳切点为350 μg/g,阴性预测值96%。
要点
- 基线FC预测6个月内症状性复发,每250 μg/g的HR为1.46(95%CI 1.21-1.77),AUC 0.82。
- FC最佳切点350 μg/g,阳性预测值41%,阴性预测值96%。
- 基线CRP预测6个月内症状性复发,每1 mg/L的HR为1.10(95%CI 1.02-1.19),AUC 0.72。
核心结论
- 粪便钙卫蛋白和CRP可预测儿童炎症性肠病临床缓解期的症状性复发,可能对管理有价值。
研究设计与样本
- 横断面队列研究,纳入114例年龄<18岁、临床缓解≥3个月的克罗恩病或溃疡性结肠炎患者;基线评估临床和生化疾病活动度,回顾性评估后续12个月病程。
主要发现
- 基线FC在发生症状性复发患者中更高[中位数(IQR),复发组370 μg/g(86-1100) vs 缓解组122 μg/g(40-344),P=0.003]。
- 基线FC预测6个月内症状性复发[每250 μg/g的HR(95%CI):1.46(1.21-1.77),P<0.001],预测准确性良好(AUC 0.82)。
- 基线CRP在发生症状性复发患者中更高[中位数(IQR),复发组1.0 μg/g(0.6-5.0) vs 缓解组1.0 μg/g(0.4-2.0),P=0.033]。
- 基线CRP预测6个月内症状性复发[每1 mg/L的HR(95%CI):1.10(1.02-1.19),P=0.011],预测准确性一般(AUC 0.72)。
关键数值与推荐
- FC最佳切点350 μg/g,阳性预测值41%,阴性预测值96%。
- CRP最佳切点1.0 mg/L,阳性预测值21%,阴性预测值94%。
临床怎么用
- 粪便钙卫蛋白和CRP可能对儿童炎症性肠病临床缓解期的管理有价值。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Reliable data on inflammatory biomarkers for predicting relapse of paediatric inflammatory bowel disease (IBD) are lacking. AIM: To investigate the predictive value of faecal calprotectin (FC) and CRP for symptomatic relapse in pediatric IBD in clinical remission. METHODS: In this cross-sectional cohort study, patients <18 years with Crohn's disease or ulcerative colitis in clinical remission ≥3 months were included. At baseline, clinical and biochemical disease activity were assessed using the abbreviated-Pediatric Crohn's Disease Activity Index or Pediatric Ulcerative Colitis Activity Index, and FC and CRP respectively. Disease course over the subsequent 12 months was retrospectively assessed. RESULTS: In total, 114 patients (56% males; median age 14.9 years) were included. Baseline FC was higher in patients that developed symptomatic relapse [median (IQR), relapse 370 μg/g (86-1100) vs. remission 122 μg/g (40-344), P = 0.003]. Baseline FC was predictive of symptomatic relapse within 6 months [HR per 250 μg/g (95% CI): 1.46 (1.21-1.77), P < 0.001], with good predictive accuracy (AUC: 0.82). Optimal FC cut-off was 350 μg/g, with positive and negative predictive value of 41% and 96%. Baseline CRP was higher in patients that developed symptomatic relapse [median (IQR), relapse 1.0 μg/g (0.6-5.0) vs. remission 1.0 μg/g (0.4-2.0), P = 0.033]. Baseline CRP was predictive of symptomatic relapse within 6 months from baseline [HR per 1 mg/L (95% CI): 1.10 (1.02-1.19), P = 0.011], with fair predictive accuracy (AUC: 0.72). Optimal CRP cut-off was 1.0 mg/L, with positive and negative predictive value of 21% and 94%. CONCLUSIONS: Faecal calprotectin and CRP are predictive of symptomatic relapse and may be valuable in management of paediatric IBD in clinical remission.
引用
- Diederen K, Hoekman DR, Leek A, et al. Raised faecal calprotectin is associated with subsequent symptomatic relapse, in children and adolescents with inflammatory bowel disease in clinical remission. Aliment Pharmacol Ther. 2017. PMID: 28138990. doi:10.1111/apt.13950
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。